Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jan 4, 2023 (4 years ago)

SINUVA (mometasone furoate)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Dissolution Specification; product did not meet the average 24-hour drug release rate (dissolution) specification stability time point at 9 months.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

SINUVA (mometasone furoate) sinus implant, 1350 mcg, 1 implant per pouch, Rx Only, intersect ENT, 1555 Adams Drive, Menlo Park, CA 94025, NDC 10599-003-01.

Affected NDC 10599-0003-01

Compare with the code on your package — it is the most precise check available.

Drug: Mometasone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Sinuva
mometasone furoate
NDC 10599-0003
1350 ug/1 Implant
Intrasinal
Intersect ENT, Inc. Rx
Recalling firm
Intersect ENT, Inc.
NDC code
10599-003-01
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0167-2023 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Mometasone recalls

See all

Other dissolution failure recalls from 2023

All dissolution failure recalls